Product News from the May 6th MM&M News Brief

Share this article:

PRODUCT NEWS
The FDA yesterday approved GlaxoSmithKline's Requip, a treatment for restless legs syndrome, a condition that can disrupt sleep and daily activities.

Amylin announced FDA approval of Byetta for treatment of patients with Type 2 diabetes. Byetta will be available by June 1, 2006, Amylin said.

The FDA has approved GlaxoSmithKline's Boostrix, the first combination vaccine that provides a booster immunization against pertussis (whooping cough) in combination with tetanus and diphtheria for adolescents.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in Business Briefs

FDA lifts OncoMed partial hold

The FDA froze the clinical trial of anti-Fzd7 vantictumab in July over concern about "bone-related adverse events."

Research links estrogen and binge eating

Baylor College of Medicine researchers have found that an estrogen replacement suppressed binge-eating behavior among lab mice.

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.